



CiteSpace v. 5.2.R4 (64-bit) Advanced
December 26, 2023 at 5:03:02 PM CST
Work: D:\biomed\margaret\immunoutput
Timespan: 2000-2023 (Slice Length=1)
Selection Criteria: g-index (k=25), LRF=3.0, LNI=10, LBY=5, e=1.0
Network: N=519, E=2249 (Density=0.0167)
Largest CCs: 452 (87%)
Nodes Labeled: 1.0%




Supplementary Figure 1 Institutional Collaboration Network Diagram. Domestic and foreign institutions tend to prefer collaborating with units within their own country.




Supplementary Figure 2 Journal article density chart. "*Frontiers in Oncology*" is the journal with the greatest number of articles in this area, followed by "*Frontiers in Immunology*", "*Cancers*", and "*Journal for Immunotherapy of Cancer*".

CiteSpace, v. 6.2.R4 (64-bit) Advanced
December 26, 2023 at 5:21:23 PM CST
WoS: D:\bibliometric\gisator\new\output
Timespan: 2000-2023 (Slice Length=1)
Selection Criteria: g-index (k=25), LRF=3.0, L/N=10, LBY=5, e=1.0
Network: N=1436, E=7633 (Density=0.0078)
Largest 30 CCs: 1304 (90%)
Nodes Labeled: 1.0%
Pruning: None



Supplementary Figure 3 10 authors who have received the most citations and co-citations. The most often mentioned author, Fuchs CS, Jemal A, and Bang YJ, is linked to the largest node.



Supplementary Figure 4 The keyword density graph.

Supplementary Table 1 The top 10 most cited journals

Rank	Cited journal	Co-citation	IF (2020)	Quartile in category
1	<i>Clinical Cancer Research</i>	1721	11.5	Q1
2	<i>Cancer Research</i>	1658	11.2	Q1
3	<i>Nature</i>	1561	64.8	Q1
4	<i>Journal Of Clinical Oncology</i>	1488	45.4	Q1
5	<i>Lancet</i>	1434	168.9	Q1
6	<i>The New England Journal Of Medicine</i>	1353	158.5	Q1
7	<i>Journal Of The American Medical Association</i>	1257	82.9	Q1
8	<i>Journal Of Clinical Oncology</i>	1243	50.5	Q1
9	<i>Journal Of Cancer</i>	1233	56.9	Q1
10	<i>International Journal Of Cancer</i>	1181	6.4	Q1

IF: Impact factor.

Supplementary Table 2 The top 10 most co-cited articles

Rank	Title	Journal (2021)	IF	Ref.	Total citations
1	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial	<i>JAMA Oncology</i>	(IF = 28.4)	Fuchs <i>et al</i> [1]	394
2	Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	<i>CA: A Cancer Journal For Clinicians</i>	(IF = 10.2)	Sung <i>et al</i> [2]	363

		= 254.7)		
3	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial	Lancet (IF = 168.9)	Kang <i>et al</i> [3]	339
4	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer	Nature Medicine (IF = 82.9)	Kim <i>et al</i> [4]	310
5	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial	Lancet (IF = 168.9)	Janjigian <i>et al</i> [5]	287
6	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial	Lancet (IF = 168.9)	Shitara <i>et al</i> [6]	286
7	Gastric cancer [7]	Lancet (IF = 168.9)	Smyth <i>et al</i> [7]	215
8	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The	JAMA Oncology (IF = 28.4)	Shitara <i>et al</i> [8]	200

	KEYNOTE-062 Phase 3 Randomized Clinical Trial [8]			
9	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial [9]	<i>Lancet Oncology</i> (IF = 51.1)	Muro <i>et al</i> [9]	176
10	Comprehensive characterization of gastric adenocarcinoma [10]	molecular gastric	Nature (IF = 64.8)	Cancer Genome Atlas Research Network[10] 152

IF: Impact factor.

Reference

- 1 **Fuchs CS**, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. *JAMA Oncol* 2018; **4**: e180013 [PMID: 29543932 DOI: 10.1001/jamaoncol.2018.0013]
- 2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]
- 3 **Kang YK**, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-

blind, placebo-controlled, phase 3 trial. *Lancet* 2017; **390**: 2461-2471 [PMID: 28993052 DOI: 10.1016/S0140-6736(17)31827-5]

4 **Kim ST**, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* 2018; **24**: 1449-1458 [PMID: 30013197 DOI: 10.1038/s41591-018-0101-z]

5 **Janjigian YY**, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021; **398**: 27-40 [PMID: 34102137 DOI: 10.1016/S0140-6736(21)00797-2]

6 **Shitara K**, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2018; **392**: 123-133 [PMID: 29880231 DOI: 10.1016/S0140-6736(18)31257-1]

7 **Smyth EC**, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. *Lancet* 2020; **396**: 635-648 [PMID: 32861308 DOI: 10.1016/S0140-6736(20)31288-5]

8 **Shitara K**, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Taberero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. *JAMA Oncol* 2020; **6**: 1571-1580 [PMID: 32880601 DOI: 10.1001/jamaoncol.2020.3370]

9 **Muro K**, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. *Lancet Oncol* 2016; **17**: 717-726 [PMID: 27157491 DOI: 10.1016/S1470-2045(16)00175-3]

10 **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; **513**: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]